May 5, 2010 (FinancialWire) — BioTime, Inc. (AMEX: BTIM), a biotechnology firm that develops and markets products in the field of human stem cells and regenerative medicine, said that it has completed its acquisition of the Singapore-based ES Cell International Pte Ltd.

ESI, which was established in 2000, is engaged in the development of human embryonic stem cell technology, being one of the initial providers of human embryonic stem cell lines to the research community.

The company filed many early stem cell patent applications, and built various relationships within the worldwide stem cell research community, according to BioTime.

ESI’s assets include a bank of six new clinical-grade human embryonic stem cell lines produced following the principles of current Good Manufacturing Practice, and equity in the Israel-based stem cell therapeutics company Cell Cure Neurosciences, Ltd.

BioTime said it expects that the addition of ESI’s assets and scientific team will enable it to more quickly develop its research products and potential therapeutic products, and establish new commercial relationships.

California-based BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly-owned subsidiary, Embryome Sciences, Inc.

BioTime’s subsidiary OncoCyte focuses on the therapeutic applications of stem cell technology in cancer. BioTime also plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, and musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia.

In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic surgery, and technology for use in surgery, emergency trauma treatment, and other applications. BioTime’s lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, and in South Korea by CJ CheilJedang under exclusive licensing agreements.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [mrgrsacqstns]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.